KKH Advisors

Sharing our CEO Thomas Oxley’s fireside chat at Forbes CIO Summit about #BCIs with Alex Knapp. ???? Watch the replay here: https://lnkd.in/eZjba3mF

Thanks to everyone who supported our poster at American College of Rheumatology Convergence 2024. ???? We presented new in vivo data demonstrating our selective BRD4 (BD2) inhibitor DC-9476 is superior to anti-TNFα, anti-IL6 and JAK2 inhibitor (tofacitinib) therapy in the collagen induced arthritis (CIA) mouse model. Read our #ACR2024 press release: https://lnkd.in/ekhAs4Jd

Thrilled to see?eGenesis, Inc.'s Wenning Qin and?Synchron's Riki Banerjee on? Fierce Biotech's 2024 Fiercest Women in Biotech List!??? https://lnkd.in/gciripAB

WOW: What an incredible coverage by so many news outlets and newsletters. Go Jimini! ?? ?? ?? Incredibly product to partner with this not only with the incredible Jimini team, but also with the amazing Dylan Reid/Zetta Venture Partners, Dr. Gal/LionBird, as well as Pavan & Enke, Mukaya, Greg & Matias, Meyer, Barak, Michael, Elana, Joshua & Rachel, Aditya, and more!

We are excited to share that an article discussing the treatment of conjunctival melanoma cell lines with bel-sar was recently published in IOVS, an Association for Research in Vision and Ophthalmology (ARVO) Journal. A special thanks to Dr. Martine Jager for her partnership on the article. A link to the full article can be found here: bit.ly/3YJVyJk

"We are developing an implantable brain computer interface... It's really life changing for these patients." Synchron CEO Thomas Oxley spoke about the work his company is doing with Forbes senior editor Alex Knapp at the 2024 #ForbesCIO Summit in New York City. https://lnkd.in/eS_Mtt9P

We’re proud to represent 3 out of the 10 women in this year’s Fierce Biotech Fiercest Women in Life Sciences. ?????? Congratulations to all and excited to continue supporting these incredible companies, technologies and therapies to reach patients in need. https://lnkd.in/gciripAB

Unnatural Products Inc. appoints Simon Bailey as Chief Operating Officer and President of R&D: https://lnkd.in/eJhFdKqM

Cellino hosted their second annual Personalized RegenMed Forum last week. ???? The exclusive two-day event brought together scientists, industry leaders, patient advocates, and pioneers in #AI and #regenerative #medicine from five countries to explore the future of curative therapies. The Forum featured prominent speakers including: Susan Hockfield, Ph.D., President Emerita of Massachusetts Institute of Technology Vinod Khosla, Founder of Khosla Ventures Sue Siegel, Board Member of Align, Nevro, Illumina, KFF, and Chairman of the Board of The Engine Accelerator “It was truly inspiring to converge with such a remarkable group of global innovators,” said Nabiha Saklayen, Ph.D., CEO & Co-Founder of Cellino. “This year’s theme, “Catalyze,” marks a critical inflection point in reshaping healthcare through personalized regenerative medicine. Our vision is to accelerate a future where autologous cell, tissue, and organ replacement therapies are not just aspirational but accessible to everyone in need.“ Read the release: ????

Thanks Bioworld for covering our #ACR2024 presentation this week. The bromodomain and extra terminal domain (BET) family of proteins, including BRD4, regulates the transcription of multiple proinflammatory and immunoregulatory genes. BRD4 is involved in immune-related disorders such as rheumatoid arthritis (RA). https://lnkd.in/e65KcM5m